➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Baxter
Merck
McKinsey
Johnson and Johnson

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SEVELAMER HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sevelamer Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018135 Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals Completed National Center for Research Resources (NCRR) N/A 1969-12-31 Patients on hemodialysis tend to have chronic elevations in the level of phosphorus in the blood and a secondary increase in the iPTH level. This chronic elevation in iPTH can have adverse consequences, thus a variety of phosphate binders are given in an attempt to decrease the absorption of phosphorus present in the normal diet. Some preliminary studies have indicated that the iPTH level may change based on the amount of phosphorus present in a meal prior to any significant absorption of phosphorus. If this is true in hemodialysis patients, then the timing of the administration of phosphate binders in relation to the ingestion of meals needs to be considered
NCT00151918 Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease Completed Shire Phase 3 2005-01-01 The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride
NCT00196755 Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis Completed Genzyme, a Sanofi Company Phase 3 2004-12-01 The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.
NCT00211939 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed Nabi Biopharmaceuticals Phase 4 2005-01-01 The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.
NCT00267514 Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients Completed Genzyme, a Sanofi Company Phase 3 2006-01-01 The purpose of this study is to determine if sevelamer carbonate powder is an effective treatment for the control of serum phosphorous levels in patients on dialysis when compared to sevelamer hydrochloride tablets.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sevelamer Hydrochloride

Condition Name

Condition Name for Sevelamer Hydrochloride
Intervention Trials
Hyperphosphatemia 20
Chronic Kidney Disease 19
Kidney Failure, Chronic 5
Hemodialysis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sevelamer Hydrochloride
Intervention Trials
Kidney Diseases 43
Renal Insufficiency, Chronic 39
Hyperphosphatemia 26
Kidney Failure, Chronic 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sevelamer Hydrochloride

Trials by Country

Trials by Country for Sevelamer Hydrochloride
Location Trials
United States 168
France 18
United Kingdom 16
Japan 12
Italy 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sevelamer Hydrochloride
Location Trials
California 13
New York 13
Texas 12
Illinois 10
Colorado 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sevelamer Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Sevelamer Hydrochloride
Clinical Trial Phase Trials
Phase 4 13
Phase 3 24
Phase 2 17
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sevelamer Hydrochloride
Clinical Trial Phase Trials
Completed 46
Recruiting 13
Not yet recruiting 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sevelamer Hydrochloride

Sponsor Name

Sponsor Name for Sevelamer Hydrochloride
Sponsor Trials
Genzyme, a Sanofi Company 19
Shire 7
Fresenius Medical Care North America 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sevelamer Hydrochloride
Sponsor Trials
Industry 56
Other 47
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
AstraZeneca
Mallinckrodt
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.